Progress in the clinical application of the positron emission tomography-computed tomography imaging in ocular adnexal lymphoma

doi:10.3877/cma.j.issn.2095-2007.2023.02.007

Abstract

Abstract:

Ocular adnexal lymphoma is a common malignant tumor of adult ocular adnexa, which has complex pathological types and various clinical features and can occur at any age.The positron emission tomography-computed tomography(PET-CT) can provide the evidence for the formulation of initial staging and treatment strategy, which is also used to evaluate the efficacy and prognosis of ocular adnexal lymphoma. The progress of PET-CT in the clinical application of ocular adnexal lymphoma was reviewed in this paper.

Key words: Positron emission tomography-computed tomography, Lymphoma, Ocular adnexa, Diagnosis and prognosis

Xuan Zhang, Rui Liu, Jing Li, Jianmin Ma. Progress in the clinical application of the positron emission tomography-computed tomography imaging in ocular adnexal lymphoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(02): 99-103.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.02.007

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I02/99

Figures/Tables 1

References 52

[1]	Mugnaini EN, Ghosh N. Lymphoma[J]. Prim Care, 2016, 43(4): 661－675.
[2]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375－2390.
[3]	Shields JA, Shields CI, Scartozzi R. Survey of 1246 patients withorbital tumors and simulating lesions[J]. Ophthalmology, 2004, 111(5): 997－1008.
[4]	Ohtsuka K, Hashimoto M, Suzuki Y. A review of 244 orbital tumors in Japanese patients during a 21－year period: origins and locations[J]. Jpn J Ophthalmol, 2005, 49(1): 49－55.
[5]	何彦津，宋国祥，丁莹. 3476例眼眶占位病变的组织病理分类[J]. 中华眼科杂志，2002，38(7)：396－398.
[6]	游启生，李彬，周小鸽，等. 112例眼附属器淋巴增生性病变临床组织病理学初步分析[J]. 中华眼科杂志，2005，41(10)：871－876.
[7]	Feery JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa：a study of 353 cases[J]. Am J Surg Pathol, 2007, 31(2)：170－184.
[8]	胡轶，何为民. 眼附属器淋巴瘤的临床病理分析[J]. 国际眼科杂志，2019，19(6)：1082－1085.
[9]	Sniegowski MC, Roberts D, Bakhoum M, et al. Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventhedition staging guidelines[J]. Br J Ophthalmol, 2014, 98(9): 1255－1260.
[10]	Demirci H, Shields CL, Karatza EC, et al. Orbital lympho－proliferative tumors: analysis of clinical features and systemic involvement in 160 cases[J]. Ophthalmology, 2008, 115(9): 1626－1631.
[11]	Alkatan HM, Alaraj A, El－Khani A, et al. Ocular adnexal lymphoproliferative disorders in an ophthalmic referral center in Saudi Arabia[J]. Saudi J Ophthalmo, 2013, 27(3): 227－230.
[12]	Oh DE, Kim YD. Lymphoproliferative diseases of the ocular adnexa in Korea[J]. Arch Ophthalmol, 2007, 125(12): 1668－1673.
[13]	Coupland SE, Hellmich M, Auw－Haedrich C, et al. Prognostic valueof cell－cycle markers in ocular adnexal lymphoma: an assessment of 230 cases[J]. Graefes Arch Clin Exp Ophthalmol, 2004, 242(2): 130－145.
[14]	孙梅，马建民. 眼眶淋巴瘤流行病学特点[J]. 中华实验眼科杂志，2020，38(11)：979－982.
[15]	Schaffel R, Hedvat CV, Teruya－Feldstein J, et al. Prognostic impactof proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma[J]. Ann Oncol, 2010, 21(1): 133－139.
[16]	White VA. Understanding and classification of ocular lymphomas[J]. Ocul Oncol Pathol, 2019, 5(6): 379－386.
[17]	Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa associated lymphoid tissue lymphoma[J]. BMC Ophthal－mol, 2020, 20(1): 24.
[18]	Kiesewetter B, Lukas J, Kuchar A, et al. Clinical features, treatment and outcome of mucosa－associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients[J]. PLoS One, 2014, 9(7): e104004.
[19]	Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra－low－dose radiotherapy for definitive management of ocular adnexal B－cell lymphoma[J]. Head Neck, 2017, 39(6): 1095－1100.
[20]	Jakobiec FA. Ocular adnexal lymphoid tumors progress in need of clarification[J]. Am J Ophthalmol, 2008, 145: 941－950.
[21]	Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa[J]. Blood, 2009, 114: 501－510.
[22]	Coupland SE, White VA, Rootman J, et al. A TNM－based clinical staging system of ocular adnexal lymphomas [J]. Arch Pathol Lab Med, 2009, 133(8): 1262－1267.
[23]	Graue GF, Finger PT, Maher E, et al. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor [J]. Eur J Ophthalmol, 2013, 23(3): 344－355.
[24]	Beyer T, Townsend DW, Blodgett TM. Dual－modality PET/CT tomography for clinical oncology[J]. Q J Nucl Med, 2002，46(1): 24－34.
[25]	Kalemaki MS, Karantanas AH, Exarchos D, et al. PET/CT and PET/MRI in ophthalmic oncology[J]. Int J Oncol, 2020, 56(2): 417－429.
[26]	张蕾，宋国祥．PET/CT在眼部肿瘤诊断中的应用[J]. 中华实验眼科杂志，2015，33: 380－384.
[27]	Finger PT, Chin K, Iacob CE. 18－Fluorine－Labelled 2－deoxy－2－fluoro－D－glucose positrone mission tomography/computed tomography standardised uptake values: a non－invasive biomarker for the risk of metastasis from choroidal melanoma[J]. Br J Ophthalmol, 2006, 90(10): 1263－1266.
[28]	Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non－hodgkin lymphoma: the lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059－3068.
[29]	Bunyaviroch T, Coleman RE. PET evalution of lung cancer[J]. J Nucl Med, 2006, 47(3): 451－469.
[30]	Blodgett T, Meltzer CC, Townsend DW. PET/CT: form and function[J]. Radiology, 2007, 242(2): 360－385.
[31]	Fletcher JW, Djulbegovic B, Soares HP, et al. Recommen－dations on the use of ¹⁸F－FDG PET in oncology[J]. J Nucl Med, 2008, 49(3): 480－508.
[32]	Elstrom R, Guan L, Baker G, et al. Utility of FDG－PET scanning in lymphoma by WHO classification[J]. Blood, 2003, 101: 3875－3876.
[33]	Wöhrer S, Jaeger U, Kletter K, et al. ¹⁸F－fluoro－deoxy－glucose positron emission tomography (¹⁸F－FDG－PET) visualizesfollicular lymphoma irrespective of grading[J]. Ann Oncol, 2006, 17(5): 780－784.
[34]	Seam P, Juweid ME, Cheson BD. The role of FDG－PET scans in patients with lymphoma[J]. Blood, 2007, 110(10): 3507－3516.
[35]	Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of ¹⁸F－fluorodeoxyglucose positron emission tomography(¹⁸F－FDG－PET )and a comparison of ¹⁸F－FDG－PET with ⁶⁷gallium scintigraphy in the evaluation of lymphoma: relationto histologic subtypes based on the World Health Organization classification[J]. Cancer, 2007, 110: 652－659.
[36]	Karam M, Novak L, CyriacJ, et al. Role of fluorine－18 fluoro－deoxyglucose positron emission tomography scan in the evaluation and follow－up of patients with low－grade lymphomas[J]. Cancer, 2006, 107(1): 175－183.
[37]	Burrell SC, van－den－Abbeele AD. 2－Deoxy－2－[F－18]fluoro－D－glucose－positron emission tomography of the head and neck: an atlas of normal uptake and variants[J]. Mol Imaging Biol, 2005, 7(3): 244－256.
[38]	王观筠，杨晖，陈佳欣，等. 眼附属器淋巴瘤¹⁸F－FDG PET－CT的代谢特征及其与临床分期的相关性[J]. 首都医科大学学报，2021，42(1)：21－25.
[39]	Jiang P, Liao SS, Lan XL, et al. Whole body positron emission tomography－computed tomography(PET－CT) in the evaluation of ophthalmic tumors[J]. Current Medical Science, 2018, 38(2): 310－317.
[40]	Zanni M, Romsee GM, Servois V, et al. Value of ¹⁸F－FDG PET scan in staging of ocular adnexal lymphomas: a large single－center experience[J]. Hematology, 2012, 17(2): 76－84.
[41]	Park HL, Oh JH, Park SY, et al. Role of ¹⁸F－FDG PET－CT in nonconjunctival origin ocular adnexal mucosa－associated lymphoid tissue (MALT) lymphomas[J]. EJNMMI Res, 2019, 9: 99.
[42]	Suga K, Yasuhiko K, Hiyama A, et al. ¹⁸F－FDG PET－CT findings in a patient with bilateral orbital and gastric mucosa－associated lymphoid tissue lymphomas[J]. Clin Nucl Med, 2009, 34(9): 589－593.
[43]	Klingenstein A, Garip－Kuebler A, Mueller－Lisse UG, et al. Combined positron emission tomography－computed tomography for diagnosis and monitoring of orbital adnexal lymphoma[J]. Acta Ophthalmol, 2018, 96: 712－717.
[44]	Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa[J]. Blood, 2009, 114(3): 501－510.
[45]	Rasmussen JH, Vogelius IR, Fischer BM, et al. Prognostic value of ¹⁸F－fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma[J]. Head Neck, 2015, 37(9)：1274－1281.
[46]	郑营营，杨忠毅. PET－CT显像在头颈部肿瘤中的临床应用进展[J]. 中国癌症杂志，2017，27(6)：425－431.
[47]	Albano D, Giubbini R, Bertagna F. ¹⁸F－FDG PET－CT in splenic marginal zone lymphoma[J]. Abdom Radiol(NY), 2018, 43(10): 2721－2727.
[48]	Wang W, Ni X, Tang T, et al. The role of ¹⁸F－FDG PET－CT in diagnosis and treatment evaluation for ocular adnexal mucosa－associated lymphoid tissue lymphoma[J]. Br J Radiol, 2022, PMID: 34919440.
[49]	Fujii H, Tanaka H, Nomoto Y, et al. Usefulness of ¹⁸F－FDG PET－CT for evaluating response of ocular adnexal lymphoma to treatment[J]. Medicine, 2018, 97(17): e0543.
[50]	Yildirim－Poyraz N, Ozdemir E, Basturk A, et al. PET－CT findings in a case with FDG－avid disseminated lacrimal gland MALToma with sequential development of large B－cell lymphoma and gastric MALToma[J]. Clin Nucl Med, 2015, 40(2): 141－145.
[51]	Saindane AM. Pitfalls in the staging of cervical lymph node metastasis[J]. Neuroimaging Clin N Am, 2013, 23(1): 147－166.
[52]	Treglia G, Zucca E, Sadeghi R, et al. Detection rate of fluorine－18－fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta－analysis[J]. Hematol Oncol, 2015, 33(3): 113－124.

Please choose a citation manager

Content to export